M&A Drives 3SBio’s Biosimilars Expansion Potential
This article was originally published in PharmAsia News
3SBio has made its second acquisition for expanded product portfolio in biosimilars and antibodies since listing in Hong Kong. The majority stake buyout deal landed on the Chinese biosimilar and antibody developer Shanghai CP Guojian Pharmaceutical. Through the integration, two companies could develop oversea markets together.
Register for our free email digests: